Clot-Removal Procedure Shows Promise Beyond Standard Stroke Cases
Two Chinese randomized trials tested catheter-based clot removal in patients with milder strokes and in those treated 24 to 72 hours after symptoms began. Both studies found better functional outcomes with the procedure than with medical care alone, but they also raised safety concerns, including bleeding and procedural complications. The results were published in the New England Journal of Medicine and may broaden eligibility for this treatment.
The MILD-MT study enrolled 304 patients across 26 Chinese comprehensive stroke centers during 2024 and 2025. It focused on mild anterior-circulation blockages with considerable tissue at risk on perfusion imaging, comparing catheter clot removal plus usual care with usual care alone within 24 hours.
LATE-MT examined clot removal 24 to 72 hours after symptoms began in patients who still had salvageable brain tissue. An accompanying editorial described both trials as important steps, while noting uncertainty about non-Asian patients, in whom heart-related embolism is a more frequent cause of large-vessel blockage.
If broader eligibility is adopted, more stroke patients—including those with milder deficits or later presentation—could be offered clot removal, potentially improving independence. Clinicians and health systems may need to weigh added procedural risks, especially bleeding and complications, and ensure careful patient selection. Access and resource demands could vary, and findings from Chinese trial populations may not fully translate elsewhere.